on
November 10, 2026
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
The risk appears small and data is mixed, but FDA wants patients to be aware.
on
November 10, 2026
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as…